JP2017533221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533221A5 JP2017533221A5 JP2017523500A JP2017523500A JP2017533221A5 JP 2017533221 A5 JP2017533221 A5 JP 2017533221A5 JP 2017523500 A JP2017523500 A JP 2017523500A JP 2017523500 A JP2017523500 A JP 2017523500A JP 2017533221 A5 JP2017533221 A5 JP 2017533221A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- administered
- composition according
- trifluoromethylthio
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 230000005855 radiation Effects 0.000 claims description 25
- 229940125904 compound 1 Drugs 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 210000003236 esophagogastric junction Anatomy 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- -1 3- (trifluoromethylthio) phenyl Chemical group 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- FIYXUOWXHWJDAM-UHFFFAOYSA-N methyl sulfamate Chemical compound COS(N)(=O)=O FIYXUOWXHWJDAM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072299P | 2014-10-29 | 2014-10-29 | |
| US62/072,299 | 2014-10-29 | ||
| US201562199011P | 2015-07-30 | 2015-07-30 | |
| US62/199,011 | 2015-07-30 | ||
| PCT/US2015/057064 WO2016069393A1 (en) | 2014-10-29 | 2015-10-23 | Administration of ubiquitin-activating enzyme inhibitor and radiation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533221A JP2017533221A (ja) | 2017-11-09 |
| JP2017533221A5 true JP2017533221A5 (enExample) | 2018-11-29 |
| JP6697453B2 JP6697453B2 (ja) | 2020-05-20 |
Family
ID=55858198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523500A Active JP6697453B2 (ja) | 2014-10-29 | 2015-10-23 | ユビキチン活性化酵素阻害物質及び放射線の投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10335411B2 (enExample) |
| EP (1) | EP3212651B1 (enExample) |
| JP (1) | JP6697453B2 (enExample) |
| TW (1) | TW201628621A (enExample) |
| WO (1) | WO2016069393A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6697453B2 (ja) | 2014-10-29 | 2020-05-20 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ユビキチン活性化酵素阻害物質及び放射線の投与 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2553476C2 (ru) | 2007-08-02 | 2015-06-20 | Миллениум Фармасьютикалз, Инк. | Способ синтеза ингибиторов е1-активирующего фермента |
| US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2013123169A1 (en) | 2012-02-17 | 2013-08-22 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
| JP6697453B2 (ja) | 2014-10-29 | 2020-05-20 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ユビキチン活性化酵素阻害物質及び放射線の投与 |
-
2015
- 2015-10-23 JP JP2017523500A patent/JP6697453B2/ja active Active
- 2015-10-23 WO PCT/US2015/057064 patent/WO2016069393A1/en not_active Ceased
- 2015-10-23 EP EP15854199.5A patent/EP3212651B1/en active Active
- 2015-10-23 TW TW104135034A patent/TW201628621A/zh unknown
- 2015-10-23 US US15/522,717 patent/US10335411B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533221A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| JP2016515561A5 (enExample) | ||
| JP2018502120A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2006504723A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2013501731A5 (enExample) | ||
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX373301B (es) | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. | |
| JP2016532667A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP7270235B2 (ja) | ペンタアザ大環状環複合体による組み合わせ癌免疫療法 | |
| CA2936551A1 (en) | Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases | |
| JP2014525454A5 (enExample) | ||
| JP2014534269A5 (enExample) | ||
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| WO2011101328A3 (en) | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2019524820A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| TW201043225A (en) | Antitumour combination comprising AVE8062 and sorafenib |